PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.37%
EBIT growth below 50% of TRAW's 20.08%. Michael Burry would suspect deeper competitive or cost structure issues.
-2.64%
Negative operating income growth while TRAW is at 20.08%. Joel Greenblatt would press for urgent turnaround measures.
0.38%
Net income growth under 50% of TRAW's 70.28%. Michael Burry would suspect the firm is falling well behind a key competitor.
3.04%
EPS growth under 50% of TRAW's 85.03%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
3.04%
Diluted EPS growth under 50% of TRAW's 85.03%. Michael Burry would worry about an eroding competitive position or excessive dilution.
2.54%
Share reduction more than 1.5x TRAW's 98.46%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
2.54%
Diluted share reduction more than 1.5x TRAW's 98.46%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
No Data
No Data available this quarter, please select a different quarter.
10.47%
OCF growth under 50% of TRAW's 28.87%. Michael Burry might suspect questionable revenue recognition or rising costs.
10.65%
FCF growth under 50% of TRAW's 28.87%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12900.29%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-37006.68%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-70.29%
Negative 3Y OCF/share CAGR while TRAW stands at 94.34%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-15642.97%
Negative 10Y net income/share CAGR while TRAW is at 68.35%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-43858.45%
Negative 5Y net income/share CAGR while TRAW is 68.35%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-130.01%
Negative 3Y CAGR while TRAW is 97.78%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
4179.35%
Equity/share CAGR of 4179.35% while TRAW is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
1066.60%
Positive short-term equity growth while TRAW is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19.98%
Negative asset growth while TRAW invests at 73.36%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-27.26%
We have a declining book value while TRAW shows 146.52%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-100.00%
We’re deleveraging while TRAW stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
37.07%
We increase R&D while TRAW cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
-49.28%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.